MVMD

2021

MOUNTAIN™ VALLEY MD

TICKER SYMBOLS: CSE: MVMD | FRA: 20MP | OTC: MVMDF



BUSINESS OVERVIEW

FORWARD LOOKING DISCLOSURE

Certain statements in this presentation are forward-looking information or forward-looking statements. Such information and statements, referred to herein as "forward-looking statements" are made as of the date of this presentation or as of the date of the effective date of information described in this presentation, as applicable. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (generally, forward-looking statements can be identified by use of words such as "outlook", "expects", "intend", "forecasts", "anticipates", "plans", "projects", "estimates", "envisages, "assumes", "needs", "strategy", "goals", "objectives", or variations thereof, or stating that certain actions, events or results "may", "can", "could", "would", "might", or "will" be taken, occur or be achieved, or the negative of any of these terms or similar expressions, and other similar terminology) are not statements of historical fact and may be forward-looking statements.

Such forward-looking statements are based on a number of assumptions that may prove to be incorrect, including, but not limited to: the ability of Mountain Valley to execute on its business plan; Mountain Valley's business performances; and Mountain Valley's business prospects and opportunities. Mountain Valley considers these assumptions to be reasonable in the circumstances, given the time periods for such outlook. However, there can be no assurance that any one or more of the industry, market, operational or financial targets as set out herein will be achieved. Inherent in the forward-looking statements are known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements, or industry results, to differ materially from any results, performance or achievements expressed or implied by such forward-looking statements.

Prospective investors and/or current investors should not place undue reliance on these forward-looking statements as a prediction of actual results, as a number of important factors could cause the actual outcomes to differ materially from the beliefs, plans, objectives, expectations, estimates, assumptions, and intentions expressed in such forward-looking statements. The forward-looking statements reflects Mountain Valley's current expectations and beliefs regarding future events and operating performance of Mountain Valley and is based on information currently available to Mountain Valley. Actual results may differ materially from the forward-looking statements contained herein. These risks include, but are not limited to, risks relating to dependence on key personal; access to capital; the risk of Mountain Valley's business; the risk of a change in investment return; the potential for a conflict of interest; and tax related risks. The foregoing list of factors that may affect future results is not exhaustive. When relying on forward looking statements, Investors should carefully consider the foregoing factors and other uncertainties and potential events.

The forward-looking statements contained herein is current as of the date of this presentation/ Except as required by law, Mountain Valley does not have any obligation to advise any person if it becomes aware of any inaccuracy in or omission from any forward-looking statement, nor does it intend, or assume any obligation, to update or revise these forward-looking statements to reflect new events or circumstances. **Any and all forward-looking statement included in this presentation is expressly qualified by this cautionary statement, and except as otherwise indicated, is made as of the date of this presentation.**

Mountain Valley MD (MVMD) Overview

MVMD is a biotechnology company in the business of repurposing and reformulating existing medical and non-medical compounds (drugs, vaccines, nutraceuticals, etc.). MVMD has an enhanced end to end supply chain encompassing the formulation, stabilization, storage, solubility and unique delivery methods of compounds.

The extrapolation of these technologies across generic vaccines and drugs has the potential to positively impact human and animal health globally.

MVMD offers licensing partnerships and acquisition opportunities for pharmaceutical/ nutraceutical companies.

MVMD Streamlined Commercialization Approach

New drug discovery is a considerable time and cost investment, with high rates of failure and limited discovery of new compounds. MVMD utilizes a streamlined commercialization approach, whereby repurposing drugs can be a powerful solution.

New Drug Discovery



Repurposed Drug



New Drug Discovery is capital intensive with decades of wait time and low success rate.

- **Only 1 compound gets FDA approval per 5,000 - 10,000 compounds.**
- **Costs $0.5 - 1+ Billion to take a drug to market.**
- **On average requires approx. 12 + years for drug approval.**

MVMD's streamlined approach to Drug commercialization

- **Higher probability of FDA approval.**
- **Costs $1-10 Million to take a drug to market.**
- **On average requires approx. 12 -14 months for drug approval.**

MVMD Approval Advantage

The MVMD pathway leverages the **Federal Food, Drug, and Cosmetic Act provision 505b(2)**; repurposing active ingredients presently in existing approved drug products for novel uses. The provision allows MVMD to bridge the gap between what is already known in the biotechnology space to further innovate.

Simplified approval

Simplified and less stringent approval process for repurposing a drug.

Faster to market

Approx. 14 months for market commercialization vs approx. 12+ years for new drug development.

20+ years

Proven efficacy on humans and animals.

Intellectual property

Retain intellectual property and renewed rights for generic drugs.

Cost savings

$1-10M for repurposing drug vs $0.5-1B for new drug to market.

Increased probability

of success vs new drug discovery. Only one drug approved per 5,000-10,000 compounds.

Lower risk

of adverse side effects, toxicity, etc.

Increased efficiency and efficacy

Lower dosage with increased efficiency and efficacy in body.

MVMD's Patented Technology

MVMD leverages existing approved vaccines, drugs, and nutraceuticals and uses technology to improve delivery to the body.

Quicksome™ RAPID & POWERFUL

Patented Quicksome™ liposome technology utilizes an advanced 2-step encapsulation and desiccation process to formulate normally low-bioavailable active ingredients into highly effective oral product formats.

MVMD leverages approved macrocyclic lactone drugs and enhances their solubility (potent broad-spectrum antiparasitic drugs with significant anti-viral properties).

Quicksol™ ENHANCED SOLUBILITY

Patented Quicksol™ technology utilizes an advanced solubilization technique to create injectable and liquid formulations.

Vaccines typically use an aluminium based adjuvant to trigger an improved immunogenic response.

Dose Sparing *Adjuvant*

MVMD has developed a novel adjuvant (patent pending) with a dose sparing advantage – looking at 10 to 20x advantage..



MOUNTAIN VALLEY MD™

Conventional Delivery Methods

Absorbed directly into stomach and liver where compounds are processed.

Higher Dose - Requires higher dose to activate in acidic stomach environment and counter break down by liver.

Uncertain Dosing - Higher variability depending on acidity and processing by liver.

Slow Absorption - Delayed absorption via stomach and intestine.

Organ Damage - Higher dosage causes liver and gastrointestinal damage.

MVMD Quicksome & Quicksol Technology

Bypasses stomach and liver where compounds are processed.

Lower Dose - Bypasses acidic stomach and liver.

Faster Absorption - Compounds delivered directly into bloodstream.

Precision Dosing - Decreased variability by bypassing gastrointestinal tract and liver.



4. Heart pumps and circulates the blood and compounds throughout the body.

3. Liver

Absorbed through stomach, then intestines drain into liver, where 70-80% is broken down. Approximately 30% of the compounds reach the heart and circulate to the rest of the body.



END-USER BENEFITS

Quicksome™
RAPID & POWERFUL

FAST ACTING

Delivers active ingredients into the body faster.

MINIMIZES SIDE EFFECTS

Reduces dosing and bypasses liver and gastrointestinal tract.

Rapid dissolve

Quick water-free oral dissolution

Needleless

Painless, needle-free administration

NO PILLS

Eliminates swallowing and related digestion issues.

Convenient

Easy to store, carry and consume



END-USER BENEFITS

Quicksol™ ENHANCED SOLUBILITY

FAST ACTING

Delivers active ingredients into the body faster.

MINIMIZES SIDE EFFECTS

Reduces dosing and bypasses liver and gastrointestinal tract.

ORAL AND INJECTABLE

Simplifies administration

BIOAVAILABILITY

Increased bioavailability

PRECISE DOSING

Eliminates swallowing and related digestion issues.

ELIMINATE VARIABILITY

More accurate absorption into the body, eliminating variability.

Dose Sparing Adjuvant

MVMD has developed a novel porous aluminum nanostructures for use as adjuvants in vaccines against various infectious diseases, including polio. These porous aluminum nanostructures have a high surface area for vaccine-antigen binding, provide long-term stability in aqueous media, and promote greater stability in harsh environments.

Adjuvant work (proof-of-concept study in progress at Tulane University) is critical to achieving MVMD's objective to completely eradicate polio, and additionally this program will inform significant dose sparing applications across hundreds of vaccines.

MVMD Supply Chain Enhancement

Leveraging proprietary technologies:

Quicksome™ RAPID & POWERFUL

Quicksol™ ENHANCED SOLUBILITY

Dose Sparing Adjuvant

Storage

Increased stability

Increased shelf life

Less temperature sensativity

Distribution

Cold Chain

Technology to support drug and vaccine distribution without the need for typical cold chain refrigeration.

Delivery

Unique precision dose delivery methods:

Sublingual wafer

Sublingual strips

Sublingual powder

Needleless injection

Intramuscular injection

Instillation

Topical ointment



Drug Storage & Distribution Logistics

Vaccine Stability

Vaccines require specific preservation conditions to retain stability. The instability of vaccines affect the **quality, safety and efficacy** of the biological medicinal product.

Cold Chain & Stability

- Cold chain is a vital part of the supply chain for drug and vaccine stabilization.
- Storage of most drugs and vaccines is required between 2 ˚C to 8˚C.
- 90% of developing countries do not have electrical infrastructure to support cold chain logistics that are needed.

CONSEQUENCES OF INSUFFICIENT COLD CHAIN

- Presently, improper refrigeration storage can result in spoilage and disposal of vaccines.
- $35 billion dollars a year in annual disposal of drugs/vaccines that break cold chain and/or do not have the confidence to deliver.
- Over $27 billion dollars in annual cold chain logistic costs

Cost to Humans

- 1.5M Deaths - children die every year from diseases that could have been prevented by vaccination coverage.

MVMD technology eliminates cold storage while improving drug and vaccine stabilization and transport logistics. Ultimately, saving more human lives and driving cost savings.

Making existing drugs better

Ivermectin (Ivectosol)

Presently, MVMD is advancing science with repurposed Ivermectin for other indications including COVID-19, Malaria, Cancer, Head Lice, Dengue, Zika and Yellow Fever, and a host of husbandry parasitic control applications.

Cancer:

Ivermectin's ability to modulate immune response paves its path as an adjuvant for cancer therapeutics.

Solubilized Ivermectin can now be administered intratumorally, intravenously, via infusions and/or instillation

Commencing preclinical trials to prove Ivectosol's synergy with certain chemotherapeutics and immunotherapeutics in:

- Triple negative breast cancer (TNBC)
- Metastatic melanoma
- Non-small cell lung carcinoma
- Non-muscle invasive bladder cancer

Selamectin (Selactosol)

MVMD has successfully solubilized Selamectin as a possible treatment for Tuberculosis. Preclinical trials are underway to validate the indication hypothesis.

MVMD is scheduled to initiate various pre-clinical studies to validate other indications.



MVMD

IVERMECTIN

PRECLINICAL TRIAL DATA

MVMD has comprehensive pharmacokinetic data for Ivermectin with broad implications for both human and animal health.

MVMD's solubility technology delivered an

800% increase

in bioavailability through intramuscular (IM) injection.*

500% increase

in bioavailability through sublingual compared to oral tablets.

* **Higher bioavailability % is preferred.**

MVMD's IM injection reaches T_{MAX} (the time to reach the maximum concentration of Ivermectin in the body) at 15 minutes.*

MVMD's sublingual strips had a T_{MAX} of 1 hour, a 600% increase compared to oral tablets.

The commercial oral and subcutaneous forms take between 6 and 36 hours

* **Lower Tmax preferred.**

Both MVMD applications showed zero decline in C_{MAX} (peak serum concentration that a drug achieves) over an extended timeframe of 12 hours, with gradual decline over 96 hours.*

The commercial oral tablet had a C_{max} of 36 hours for oral tablet.

MVMD had a 3x extended clearance - a very significant indication compared to oral and subcutaneous forms.

* **Lower Cmax with slower decline preferred.**

Both MVMD applications show minimal pharmacokinetic variability.*

- IM injection at zero percent variability
- Sublingual strips at 5% variability

vs. 40% variability for alternative oral tablets.

Variability contributes to the potential for adverse effects or not achieving the required therapeutic index.

* **Lower variability preferred.**



Product Applications



- **Cancer Adjuvant**
- **Dose Sparing Adjuvant**
- **Sublingual Wafers / Strips / Powders**
- **Ivermectin, Ivectosol** (Quicksome and Quicksol)
- **Mushroom-infused**
- **Removal of Cold Chain**
- **Intramuscular Injections (humans & animals)**
- **Ointments (Pain, Skin conditions)**
- **Selamectin, Selactosol (humans)**
- **Sublingual Cannabinoids**

MVMD

CANNABIS

Cannabinoid Infused Products

MVMD's Quicksome and Quicksol technologies are currently being formulated and tested to produce highly convenient cannabinoid infused sublingual products.

Presently pursuing preclinical trial to test the product's efficacy and acquire pharmacokinetic data.

Rapid absorption while using lower dose while providing convenience with dosing precision.

- Stable delivery
- Waterless oral dissolve
- Quicker onset
- Precise dosing
- Reduced variability
- Dose sparing

Key MVMD Achievements



Publicly traded company with market cap of $300+ M

16 Patents/Patents Pending across various delivery technologies, repurposing of compounds.

Solubilizing Macrocyclic Lactone Drugs

- First ever selamectin treatment for human use
- First ever Ivermectin injectable for human use
- High viscosity use for new husbandry animal applications

Preclinical trials in progress at BSL-4 Labs (highest standard laboratory with less than 30 globally, admission times of up to 3 years for study engagement)

Working with multiple universities and government agencies on trials with Ivectosol, Selactosol, cold chain and dose-sparing adjuvant

Commencing three unique pre-clinical cancer trials via contract research organizations (CRO) using Ivectosol as an adjuvant

Preclinical Tuberculosis trial using Selactosol

FDA 505(b)(2) pathway filed with the U.S. Food and Drug Administration (FDA)

- Working with FDA on investigative scientific study with IPV.

TEAM

Dennis Hancock President & CEO, Board of Directors
Aaron Triplett CFO
Mike Farber Director of Life Sciences
Antonina Szaszkiewicz Legal Counsel

BOARD OF DIRECTORS

Nancy Richardson, BA, BSc
Paul Lockhard
Kevin Puloski

PHARMA / SCIENTIFIC ADVISORY BOARD

Sid Senroy
Azhar Rana, MD
Dr. John Clements, PH.D
Dr. Michel Rondeau, M.R.

STRATEGIC ADVISORS

Evan Clifford - co-founder
Jeffrey Dignard - co-founder
Leigh Hughes



Addressable Market



MOUNTAIN VALLEY MD

We provide our partners with unprecedented market advantages while dealing with some of most significant challenges facing their companies:

Loss of Patent Exclusivity

Extending Profitability Against Generic Drug Competitors

Driving Down Drugs and Vaccine Cost While Increasing Profitability

Enabling Broader Distribution of Drugs and Vaccines

Eliminating Significant Cost and Wastage Associated with Cold Chain Storage

Expanding Production Capacity for Global Blockbuster Drugs



Revenue & Exit opportunity

Publicly traded company

Uplisting to TSX-V

Global licensing by molecule, by market

Sale of technology by various sectors

MOUNTAIN™
VALLEY MD

MOUNTAIN VALLEY MD — *HEAD OFFICE*

260 EDGELEY BLVD, UNIT 4
CONCORD, ONTARIO, CANADA
L4K 3Y4

ir@mountainvalleymd.com



Dennis Hancock President & CEO, Mountain Valley MD – Board of Directors

Dennis Hancock is a senior sales and marketing executive with over 25 years of experience spanning automotive, pharmaceutical, tech, telco, retail and financial services sectors. Initially providing consulting services to Mountain Valley MD in 2018, Dennis transitioned to assume the President & CEO position in early 2019 to lead the Company's go-public strategy and develop the business strategy to pursue broad health and wellness opportunities approach across human, animal and plant health applications. Dennis spent more than 12 years in a leadership role at one of North America's leading performance improvement and Loyalty providers, Maritz, who works with 70% of the world's Super 50 companies. Previously, Dennis led publicly traded ZENN Motor Company as the Vice President of Sales and Marketing. As a senior officer at ZMC, Dennis drove the establishment of ZENN – (Zero Emission, No Noise) as one of the most recognized "green tech" brands in North America. Dennis has several start-ups established, including PerformanceSPARK, an agency that works with leading organizations to identify and deliver on the key elements necessary to drive measurable performance growth, and co-founder of CrowdSeating Inc., an innovative social concert platform.

Aaron Triplett CFO, Mountain Valley MD

Aaron Triplett is a Chartered Professional Accountant (CPA, CA), and has accumulated over 15 years experience in the field of financial management and accounting, specializing in forecasting, compliance and risk management, and the development and monitoring of control systems. Most recently, Mr. Triplett served as CFO of Grande West Transportation Group Inc. (TSXV: BUS), a Canadian manufacturer of mid-sized multi-purpose transit vehicles for sale in Canada and the United States. Aaron was instrumental in the Company's financial growth initiatives, securing a $20 million and $5 million revolving credit facility with major Canadian banks. Prior to that, Mr. Triplett served as the CFO of Angkor Resources Corp. (TSXV: ANK), a mineral exploration company with operations in Cambodia. Mr. Triplett's work experience also includes audit and assurance manager for a mid size public accounting firm.

Mike Farber Director of Delivery Sciences

Mike Farber is MVMD's lead inventor and principal scientist. Mike's father, Harold Cyril Farber, had polio and that despite all the tragedies of this story, it was the core of Mike's personal mission to work on technology that truly has the potential to eradicate polio and it is foundational to all of the transformational work we are doing at Mountain Valley MD. Utilizing his background in biochemistry, Mike began his career in research and development doing polymer research for container-packaging company Consolidated Bathurst in Montreal. Farber has focused his attention primarily in the area of novel delivery systems for both nutraceuticals and pharmaceuticals. This work over the last two decades has led to his authoring over a hundred patents. The main focus of this work has been to improve the bioavailability of compounds to enhance effectiveness, efficiency and convenience. Mike's most important current developments include the patented desiccated liposomal rapid dissolve delivery system, macrocyclic lactone drug solubilization and novel dose sparing adjuvant.

Antonina Szaszkiewicz Legal Counsel, Mountain Valley MD

Antonina Szaszkiewicz (nee Chmielowski) is a lawyer and owner of ECS Law Professional Corporation, specializing in Entertainment, Corporate and Securities law. Antonina represents both private and public companies, and individuals, with experience in a wide variety of contractual and transactional work. She specializes in business start-ups and ongoing operations for both private and public companies: including compliance with corporate and securities regulatory requirements, shareholder meetings, financings (debt, equity), M&As, business sales and acquisitions (share or asset purchases), reorganizations, share splits/consolidations, amalgamations, going public transactions, stock exchange listings, change of business, etc.
Antonina is a licensed member of the Ontario and BC Law Societies.

Dennis Hancock President & CEO, Mountain Valley MD – Board

Nancy Richardson, BA, BSc

Nancy Richardson is a veteran of the pharmaceutical and agency world, developed continuing medical education for physicians, pharmacists and nurses for over two decades. Together with her business partner, Nancy ran a successful multi-million-dollar medical communications agency for twelve years, bringing numerous drugs to market, overseeing accounts, generating sales and managing daily operations. She is an experienced pharmaceutical marketing strategist, facilitator and project manager, who conducted countless advisory boards across the globe. Nancy successfully sold her business in 2017, and is now acting as VP of Client Service for LWT Communications, a localization agency with offices in North America and Europe.

Nancy currently serves on the Board of Directors of the Institute of Cultural Affairs Canada, an organization that brings leadership and facilitation expertise to communities in need all over the world. Nancy is also the Local Chapter Leader for the Monroe Institute in Toronto - an organization that delivers workshops and seminars on human consciousness.

Paul Lockhard

Paul Lockhard is an experienced business leader, entrepreneur and digital marketer. Over 35 years Paul has built a strong foundation in consumer goods and digital marketing for such brands as Trident Gum, Energizer Batteries, Ford, Lenscrafters, Labatt Breweries and Guardian Capital. He has founded 4 successful businesses, and helped 200+ startups over the past 19 years. He is a co-founder of Virtacore, a values-based organization of entrepreneurs and intrapreneurs, dedicated to helping other entrepreneurs launch and grow successful enterprises. Paul is currently Chief Client Officer at William Thomas Digital, a CRM agency in Toronto serving major Canadian and global companies in retail, loyalty and consumer goods.

Kevin Puloski

Kevin is an entrepreneur and visionary. With over 26 years of executive experience, he has developed an astute ability to identify global market trends and partners with key people and organizations to ensure success in all his endeavors. Kevin currently has agricultural and pharmaceutical projects for genetic development as well as strategic land acquisitions in India and Uganda. He also maintains his position as president and CEO of Pund-IT; an IT business technology firm that is focused on helping to bring technology solutions to a wide variety of industries. Kevin's love of collaboration and networking has led him to hold board positions in not-for-profit, financial, healthcare, manufacturing, and digital media organizations. He is a founding member of the Entrepreneurs Organization (EO) of South Western Ontario and continues to play an active role in the chapter.







Sid Senroy

Mr. Senroy is a seasoned pharmaceutical executive with an MBA from Pepperdine University with expertise in helping companies pass compliance assessments, develop robust quality systems and prepare for U.S. Food and Drug Administration reviews and inspections. Over the past two decades, Mr. Senroy has successfully led several global Quality and Compliance business units as an executive or senior consultant, leading to the approval of key blockbuster drugs with cumulative sales exceeding $30 billion annually over the last 10 years. Mr. Senroy's ability to form cross-functional alliances for improvement and growth, in addition to a sensitivity to cultural nuances, has helped him succeed on a global scale. He has worked extensively throughout North America, Europe, Asia and South America.

Mr. Senroy works with the leadership team on pharmaceutical licensing strategy, facilitation of strategic introductions to key pharmaceutical partners and supports the development of the Company's overall business development plan.

Azhar Rana, MD

Azhar Rana, MD, is the President of Integrated Medhealth Communication (IMC) North America and is a trained general medicine practitioner with a clinical background and has held a number of senior medical positions at Bristol-Myers Squibb, Novo Nordisk and most recently at AstraZeneca.

Dr. John Clements, PHD

Dr. John Clements is Emeritus Professor of Microbiology and Immunology at Tulane University School of Medicine. With over 35 years of experience in vaccine, immunology and infectious diseases research and development, Dr. Clements brings invaluable expertise and advisory capacity to help advance Mountain Valley MD's ongoing Quicksome™ sublingual polio vaccine development activities. Dr. Clements' distinguished scientific career has focused on developing and evaluating vaccines for a wide range of infectious diseases globally (including diarrheal diseases, Polio and HIV), including involvement in academia, research and development, governmental and vaccine advisory boards and professional journals. Dr. Clements has published more than 150 peer-reviewed papers, has 14 issued patents, and has been involved in numerous vaccine clinical trials. Dr. Clements has worked with leading vaccine focused organizations such as the Centers for Disease Control and Prevention (CDC), Food and Drug Administration (FDA), National Institutes of Health (NIH), and the United States Military.

Dr. Michel Rondeau

Michel Rondeau, Doctor of Veterinary Medicine, oversees MVMD's husbandry and companion animal studies, while driving global pharmaceutical animal applications as part of the ongoing business commercialization of MVMD's technology.

Dr. Rondeau has extensive experience in veterinary research having worked with numerous pharmaceutical companies in animal drug field trials and is credited with co-inventing a global award winning sprayable vaccination device that was acquired by Rhone Poulenc. Dr. Rondeau has completed an extensive range of research and development projects across a diverse range of husbandry animals including porcine industrial medicine across preventative and curative medicine, nutrition and animal health products and automated feed systems.





Evan Clifford - co-founder

Evan Clifford has over 18 years of extensive experience in entrepreneurial start-ups both in the private and public sector. Evan has earned a platinum record as the manager of one of Canada's most successful pop music artists, played a leading role in building one of the world's foremost electric car companies, and branched into the restaurant business as founder of the world's first 100% sustainable Ocean Wise certified sushi restaurant. In 2016, Evan orchestrated the "going public" transaction of Organic Garage (TSX-V:OG), successfully raising over $5 million for the company, and in 2018 co-founded Flower One Holdings Inc. (CSE:FONE), which raised over $100 million and owns assets in the cannabis sector including the largest licensed greenhouse in the state of Nevada.

Jeffrey Dignard - co-founder

A seasoned entrepreneur, Jeff's knowledge and expertise is steeped in 20 years of hands-on executive experience in diverse and dynamic markets including the restaurant and entertainment industries, advertising, global sales and financial investment profiles. A big-picture thinker, Jeff recognizes the need for structure to advance true creative vision. His keen sense of vision are anchored in practical strategies and tactics. Jeff has served as a strategic advisor in the development of the medicinal cannabis market for 12 years.

Leigh Hughes

Mr. Hughes brings over fifteen years of professional experience in integrated corporate and marketing communications and extensive experience in venture capital services and commercialization of private and public companies across the globe: North America, Australia, and the Asia Pacific Region.
Mr. Hughes supports the Company's work in the areas of mergers and acquisitions, corporate finance and pharmaceutical licensing.